Title
Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: Effects of adalimumab versus placebo
Author
TNO Kwaliteit van Leven
Tak, P.P.
van Kuijk, A.W.R.
de Groot, J.
Koeman, R.C.
Sakkee, N.
Baeten, D.L.
Gerlag, D.M.
Publication year
2010
Abstract
Background: There is growing interest in soluble biomarkers that could be used on the group level for screening purposes in small proof of principle studies during early drug development. We investigated early changes in serum levels of several candidate biomarkers involved in cartilage and bone metabolism following the initiation of adalimumab as a prototypic active treatment in psoriatic arthritis (PsA) compared to placebo. Materials and Methods: Twenty-four PsA patients were randomized to receive either adalimumab 40 mg s.c. every other week or placebo for 4 weeks, followed by an open label extension phase. Serum samples were obtained at baseline and after 4 and 12 weeks of treatment and analyzed for levels of CPII and PINP (synthesis of type II and type I procollagen), melanoma inhibitory activity (MIA) (chondrocyte anabolism), matrix metalloproteinase (MMP)-3, C2C and cartilage oligomeric matrix protein (COMP) (type II collagen degradation), osteocalcin (OC) (bone formation), NTX-I and ICTP (both type I collagen degradation). Results: After 4 weeks, there was a significant decrease in serum MMP-3 levels in adalimumab-treated patients (P
Subject
Biomedical Research
adalimumab
amino terminal cross linked telopeptide of type 1 collagen
C propeptide of type 2 collagen
carboxy terminal cross linked telopeptide of type 1 collagen
cartilage oligomeric matrix protein
collagen type 1
collagen type 2
osteocalcin
placebo
procollagen
procollagen serum type 1 amino terminal propeptide
stromelysin
unclassified drug
article
bone metabolism
cartilage cell
cartilage metabolism
clinical article
clinical trial
controlled clinical trial
controlled study
correlation analysis
disease marker
drug efficacy
human
ossification
protein analysis
protein blood level
protein degradation
protein function
protein synthesis
psoriatic arthritis
randomized controlled trial
tissue metabolism
To reference this document use:
http://resolver.tudelft.nl/uuid:7f6b914c-4556-4f2b-bdbe-87584f561f5a
TNO identifier
425154
ISSN
1932-6203
Source
PLoS ONE, 5 (5), 1-5
Document type
article